

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: HAQUE ET AL. Examiner: UNKNOWN
Serial No.: 10/729,276 Group Art Unit: UNKNOWN
Filed: DECEMBER 3, 2003 Docket: 12695.13USD2
Confirmation No.: UNKNOWN
Due Date: MARCH 3, 2004
Title: TREATMENT OF CEREBROVASCULAR DISEASE

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 3, 2004.

By: 

Name: Tracy Gite-Vukobovich

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

23552

PATENT TRADEMARK OFFICE

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Information Disclosure Statement, Form 1449
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.


MERCHANT & GOULD P.C.
P.O. Box 2903, Minneapolis, MN 55402-0903
612.332.5300

By: 

Name: Anna M. Nelson

Reg. No.: 48,935

ANelson:PLStov



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: HAQUE ET AL. Examiner: UNKNOWN
Serial No.: 10/729,276 Group Art Unit: UNKNOWN
Filed: DECEMBER 3, 2003 Docket: 12695.13USD2
Confirmation No.: UNKNOWN
Due Date: MARCH 3, 2004
Title: TREATMENT OF CEREBROVASCULAR DISEASE

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 3, 2004.

By: _____
Name: Tracy J. Vucanovich

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

23552

PATENT TRADEMARK OFFICE

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Information Disclosure Statement, Form 1449
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.
P.O. Box 2903, Minneapolis, MN 55402-0903
612.332.5300

By: Anna M. Nelson
Name: Anna M. Nelson
Reg. No.: 48,935
ANelson:PLStov



S/N 10/729,276

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	HAQUE ET AL.	Examiner:	UNKNOWN
Serial No.:	10/729,276	Group Art Unit:	UNKNOWN
Filed:	DECEMBER 3, 2003	Docket No.:	12695.13USD2
Title:	TREATMENT OF CEREBROVASCULAR DISEASE		

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 2, 2004.

By:

Name: Tracy J. Buchanan

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted within three months of the filing date of the above-identified application, which is not an application under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(d), a copy of each document or other information listed on the enclosed Form 1449 is not provided because it was previously cited by or submitted to the U.S. Patent and Trademark Office in parent applications, U.S. Serial Nos. 10/254,197 filed on September 24, 2002 and 09/820,199 filed on March 28, 2001, now U.S. Patent No. 6,586,414. In accordance with 37 C.F.R. § 1.98(a)(2), a copy of U.S. Patent No. 6,586,414 listed on the enclosed Form 1449 is not provided, as this application was filed after June 30, 2003.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to

establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,


MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date:


March 3, 2004



Anna M. Nelson
Reg. No. 48,935
AMN:PLStov



FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: HAQUE ET AL.	
	Filing Date: 12/03/2003	Group Art Unit: UNKNOWN




U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	3,206,463	09/14/1965	Baetz			
	3,910,921	10/07/1975	Esanu			
	3,987,177	10/19/1976	Giudicelli et al.			
	4,032,534	06/28/1977	Chodkiewicz			
	4,036,844	07/19/1977	Thorne et al.			
	4,053,607	10/11/1977	Thorne et al.			
	4,137,316	01/30/1979	Esanu			
	4,167,562	09/11/1979	Evers			
	4,361,570	11/30/1982	Fici			
	4,369,172	01/18/1983	Schor et al.			
	4,374,841	02/22/1983	Descamps et al.			
	4,515,771	05/07/1985	Fine			
	4,567,179	01/28/1986	Lombardino			
	4,569,938	02/11/1986	Esanu			
	4,569,939	02/11/1986	Esanu			
	4,581,363	04/08/1986	Esanu			
	4,605,741	08/12/1986	Zagnoli et al.			
	4,730,042	03/08/1988	Hege et al.			
	4,735,950	04/05/1988	Esanu			
	4,735,956	04/05/1988	Baldwin et al.			
	4,837,239	06/06/1989	Benjamin et al.			
	4,843,071	06/27/1989	Hohenwarter			
	4,962,121	10/09/1990	Hamberger et al.			
	5,001,115	03/19/1991	Sloan			
	5,053,396	10/01/1991	Blass			
	5,118,505	06/02/1992	Költringer			
	5,130,324	07/14/1992	Ulrich et al.			
	5,132,115	07/21/1992	Wolter et al.			
	5,210,083	05/11/1993	Pfirrmann			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: HAQUE ET AL.	
	Filing Date: 12/03/2003	Group Art Unit: UNKNOWN



	5,213,813	05/25/1993	Kornecki et al.			
	5,254,557	10/19/1993	Buckle et al.			
	5,254,572	10/19/1993	Serfontein			
	5,272,165	12/21/1993	Ulrich et al.			
	5,278,154	01/11/1994	Lacoste et al.			
	5,288,716	02/22/1994	Speck			
	5,326,757	07/05/1994	Demopoulos			
	5,328,453	07/12/1994	Sibalis			
	5,372,999	12/13/1994	Schneider et al.			
	5,385,937	01/31/1995	Stamler et al.			
	5,420,112	05/30/1995	Lewis et al.			
	5,441,972	08/15/1995	Ogata et al.			
	5,504,090	04/02/1996	Neely			
	5,563,126	10/08/1996	Allen et al.			
	5,569,459	10/29/1996	Shlyankevich			
	5,569,648	10/29/1996	Lewis et al.			
	5,631,271	05/20/1997	Serfontein			
	5,633,228	05/27/1997	Lewis et al.			
	5,648,335	07/15/1997	Lewis et al.			
	5,728,684	03/17/1998	Cheng et al.			
	5,733,884	03/31/1998	Barbul et al.			
	5,733,916	03/31/1998	Neely			
	5,770,215	06/23/1998	Moshhyedi			
	5,795,873	08/18/1998	Allen			
	5,804,163	09/08/1998	Gibby et al.			
	5,804,594	09/08/1998	Murad			
	5,833,998	11/10/1998	Biedermann et al.			
	5,834,446	11/10/1998	Dow et al.			
	5,840,685	11/24/1998	Fujii et al.			
	5,847,008	12/08/1998	Doebber et al.			
	5,858,017	01/12/1999	Demopulos et al.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: HAQUE ET AL.	
	Filing Date: 12/03/2003	Group Art Unit: UNKNOWN

	5,859,051	01/12/1999	Adams et al.			
	5,874,420	02/23/1999	Pelleg			
	5,874,443	02/23/1999	Kiely et al.			
	5,888,514	03/30/1999	Weisman			
	5,944,020	08/31/1999	Markov et al.			
	6,043,259	03/28/2000	Dhalla et al.			
	6,310,093	10/30/2001	Newcomb			
	6,339,085	01/15/2002	Haque			
	6,586,414 B2	07/01/2003	Haque et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	831,350	01/14/1976	BE				X
	863,754	05/29/1978	BE				X
	561 183	04/30/1975	CH				X
	1 958 226	05/27/1970	DE				X
	37 05 549 A1	09/01/1988	DE				X
	43 44 751 A1	06/29/1995	DE				X
	24 61 742 A	07/08/1976	DT				X
	0 121 036 A1	10/10/1984	EP				
	0 144 051 A2	06/12/1985	EP				
	0 270 026 A2	06/08/1988	EP				
	0 416 248 A2	03/13/1991	EP				
	0 891 719 A1	01/20/1999	EP				
	846,376	03/26/1941	FR				X
	1,323,941	12/15/1963	FR				X
	5,552 M	12/26/1967	FR				X
	5,801 M	03/28/1968	FR				X
	6,453 M	12/16/1968	FR				X
	1,579,544	08/29/1969	FR				X

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	


FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: HAQUE ET AL.	
	Filing Date: 12/03/2003	Group Art Unit: UNKNOWN

	2 034 539	12/11/1970	FR				X
	2,101,010	03/31/1972	FR				X
	2,255,883	07/25/1975	FR				X
	2,428,640	01/11/1980	FR				X
	1 013 939	12/22/1965	GB				
	1,172,800	12/03/1969	GB				
	1 201 014	08/05/1970	GB				
	1 297 080	11/22/1972	GB				
	1 360 536	07/17/1974	GB				
	1 493 993	12/07/1977	GB				
	2 254 556 A	10/14/1992	GB				
	48-21959	07/02/1973	JP				X
	54-17130	02/08/1979	JP				X
	WO 83/00085	01/20/1983	PCT				
	WO 91/19500	12/26/1991	PCT			Abstract	
	WO 94/18965	09/01/1994	PCT				
	WO 98/19690	05/14/1998	PCT				
	WO 99/03365	01/28/1999	PCT				
	WO 99/53928	10/28/1999	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Aybak, M. et al., "Effect of Oral Pyridoxine Hydrochloride Supplementation on Arterial Blood Pressure in Patients with Essential Hypertension", <i>Drug Res.</i> , Vol. 45, No. 12, pp. 1271-1273 (1995).
	"B Vitamins May Cut Heart Disease Risk", <i>Harvard Health Letter</i> , 1 page (1998)
	Baliga, B. et al., "Hyperhomocysteinemia in Type 2 Diabetes Mellitus: Cardiovascular Risk Factors and Effect of Treatment with Folic Acid and Pyridoxine", <i>Endocrine Practice</i> , Vol. 6, No. 6, pp. 435-441 (November/December 2000).
	Barrett, S., "Homocysteine: A Cardiovascular Risk Factor Worth Considering", http://www.quackwatch.com/03HealthPromotion/homocysteine.html , 2 pages (©1997)
	Bernstein, A., "Vitamin B ₆ in Clinical Neurology", <i>Annals of New York Academy of Sciences</i> , Vol. 585, pp. 250-260 (1990)
	Berger, A.R. et al., "Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: A prospective study of pyridoxine neurotoxicity", <i>Neurology</i> , Vol. 42, No. 7, pp. 1367-1370 (July 1992)
	Bhagavan, H. et al., "Effect of Postweanling Pyridoxine Deficiency on Growth and Concentration of the Coenzyme Pyridoxal-5'-phosphate in Heart, Kidneys, Lungs, and Adrenals in Rats", <i>Pediat. Res.</i> , Vol. 10, pp. 730-732 (1976).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT  IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: HAQUE ET AL.	
	Filing Date: 12/03/2003	Group Art Unit: UNKNOWN

	Bode, W. et al., "Pyridoxal-5'-Phosphate and Pyridoxal Biokinetics in Male Wistar Rats Fed Graded Levels of Vitamin B-6", <i>J. Nutr.</i> , Vol. 121, No. 11, pp. 1738-1745 (November 1991)
	Broll H. et al., "New Aspects in the Treatment of Cerebral Ischemia", <i>Weiner Medizinische Wochenschrift</i> , Vol. 125, No. 45, pp. 646-650 (1975)
	Chasan-Taber, L. et al., "A Prospective Study of Folate and Vitamin B ₆ and Risk of Myocardial Infarction in US Physicians", <i>Journal of the American College of Nutrition</i> , Vol. 15, No. 2, pp. 136-143 (April 1996)
	Cho, Y. et al., "In Vivo Evidence for a Vitamin B-6 Requirement in Carnitine Synthesis", <i>J. Nutr.</i> , Vol. 120, pp. 258-265 (1990)
	"Computer Generated Search Reports", 70 pages (May 1999)
	Ellis, J. et al., "Prevention of Myocardial Infarction by Vitamin B ₆ ", <i>Res. Commun. Molec. Pathol. Pharmacol.</i> , Vol. 89, No. 2, pp. 208-220 (August 1995)
	Folsom, A. et al., "Clinical Investigation and Reports: Prospective Study of Coronary Heart Disease Incidence in Relation to Fasting Total Homocysteine, Related Genetic Polymorphisms, and B Vitamins: The Atherosclerosis Risk in Communities (ARIC) Study", <i>Circulation</i> , Vol. 98, pp. 204-210 (July 21, 1998).
	Harada, K. et al., "Studies on Vitamin B ₆ . (IV) Behavior of Pyridoxal Acylates in the Body After Parenteral Administration", <i>Vitamins Journal of the Vitamin Society of Japan</i> , Vol. 45, No. 2, pp. 69-75 (February 1972)
	Hathcock, J., "Vitamins and minerals: efficacy and safety", <i>Am J Clin Nutr</i> , Vol. 66, pp. 427 - 437 (1997)
	Hoover, D.M. et al., "Ultrastructural Lesions of Pyridoxine Toxicity in Beagle Dogs", <i>Vet. Pathol.</i> , Vol. 18, pp. 769-777 (1981)
	Kok, F. et al., "Low Vitamin B ₆ Status in Patients with Acute Myocardial Infarction", <i>Am. J. Cardiol.</i> , Vol., 63, pp. 513-516 (March 1, 1989)
	Korytnyk et al. Schiff Bases of Pyridoxal: Their Structure and the Stabilization of their Ring-Chain Tautomeric Forms by Acylation, <i>Tetrahedron</i> , 26 (23), 5415-25 (1982)
	Krinke, G. et al., "Pyridoxine Megavitaminosis: An Analysis of the Early Changes Induced with Massive Doses of Vitamin B ₆ in Rat Primary Sensory Neurons", <i>J. Neuropathol. Exp. Neurol.</i> , Vol. 44, No. 7, pp. 117-129 (March 1985)
	Kubyskhin, V. et al., "Comparative characteristics of the arrhythmic syndrome and the possibility for its coenzyme correction in dilated and hypertrophic cardiomyopathy", <i>Abstract</i> , 1 pg. (1989).
	Lal, K. et al., "Hypotensive action of 5-HT receptor agonists in the vitamin B ₆ -deficient hypertensive rat", <i>Eur. J. Pharmacol.</i> , Vol. 234, Nos. 2/3, pp. 183-189 (April 1993)
	Lal, K. et al., "Calcium channels in vitamin B ₆ deficiency-induced hypertension", <i>Journal of Hypertension</i> , Vol. 11, No. 12, pp. 1357-1362 (December 1993)
	Lal, K. et al., "The effect of vitamin B ₆ on the systolic blood pressure of rats in various animal models of hypertension", <i>Journal of Hypertension</i> , Vol. 14, No. 3, pp. 355-363 (March 1996)
	Levy, H. et al., "Pyridoxine Deficiency in Congestive Heart Failure", <i>P.S.E.B.M.</i> , Vol. 101, pp. 617-621 (1959)
	Manore, M. et al., "Changes In Plasma Pyridoxal Phosphate (PLP) In Diabetic (D), Hypertensive (HTN) and Hypertensive-diabetic (HTN-D) Men Fed A Constant Vitamin B-6 (B6) Diet", <i>Source Unknown</i> , pp. 1254 (1990).
	Markov, A. et al., "Hemodynamic, electrocardiographic, and metabolic effects of fructose diphosphate on acute myocardial ischemia", <i>American Heart Journal</i> , Vol. 100, No. 5, pp. 639 - 646 (November 1980)
	Mendelsohn, A. et al., "Hemodynamic and Clinical Effects of Oral Levodopa in Children With Congestive Heart Failure", <i>JACC</i> , Vol. 30, No. 1, pp. 237-242 (July 1997).
	Merrill, Jr. et al. A. et al., "Diseases associated with defects in vitamin B ₆ metabolism or utilization", <i>Ann. Rev. Nutr.</i> , Vol. 7, pp. 137-156 (1987)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12695.13USD2	Application Number: 10/729,276
	Applicant: HAQUE ET AL.	
	Filing Date: 12/03/2003	Group Art Unit: UNKNOWN

	Mulvaney, D. et al., "Electrocardiographic changes in vitamin B ₆ deficient rats", <i>Cardiovascular Research</i> , Vol. 13, pp. 506-513 (1979).
	Omenn, G. et al., "Preventing Coronary Heart Disease", <i>Circulation</i> , Vol. 97, pp. 421-424 (1998)
	Paulose, C. et al., "Sympathetic Stimulation and Hypertension in the Pyridoxine-Deficient Adult Rat", <i>Hypertension</i> , Vol. 11, No. 4, pp. 387-391 (April 1988)
	Rao, R. et al., "Failure of Pyridoxine to Improve Glucose Tolerance in Diabetics", <i>Journal of Clinical Endocrinology & Metabolism</i> , Vol. 50, No. 1, pp. 198-200 (January 1980).
	Rimm, E. et al., "Folate and Vitamin B ₆ From Diet and Supplements in Relation to Risk of Coronary Heart Disease Among Women", <i>JAMA</i> , Vol. 279, No. 5, pp. 359-364 (February 4, 1998)
	Sakuragi, T. et al., "The Synthesis of Long Chain Fatty Acid Derivatives of the Vitamin B ₆ Group", <i>J. Am. Chem. Soc.</i> , Vol. 78, pp. 839-842 (February 20, 1956)
	Sethi, R. et al., "Differential changes in left and right ventricular adenylyl cyclase activities in congestive heart failure", <i>The American Physiological Society</i> , Vol. 272, No. 2, Part 2 of Two Parts, pp. H884 - H893 (February 1997)
	Sethi, R. et al., "Inotropic Responses to Isoproterenol in Congestive Heart Failure Subsequent to Myocardial Infarction in Rats", <i>Journal of Cardiac Failure</i> , Vol. 1, No. 5, pp. 391 - 399 (December 1995)
	Takuma, Y. et al., "Combination Therapy of Infantile Spasms With High-Dose Pyridoxal Phosphate and Low-Dose Corticotropin", <i>Journal of Child Neurology</i> , Vol. 11, No. 1, pp. 35-40 (January 1996).
	Tanaka, T. et al., "Pyridoxine Derivatives", <i>Chemical Abstracts</i> , Vol. 62, No. 12, 1 page (June 7, 1965)
	Treize, D. et al., "P ₂ purinoceptor antagonist properties of pyridoxal-5-phosphate", <i>Eur. J. Pharmacol.</i> , Vol. 259, No. 3, pp. 295-300 (July 11, 1994)
	Vanderjagt, D. et al., "Vitamin B ₆ Status in a Healthy Elderly Population", <i>Annals New York Academy of Sciences</i> , pp. 562 - 564 (1990)
	Verhoef, P. et al., "A Common Mutation in the Methylenetetrahydrofolate Reductase Gene and Risk of Coronary Heart Disease: Results Among U.S. Men", <i>JACC</i> , Vol. 32, No. 2, pp. 353 -359 (August 1998)
	Verhoef, P. et al., "Homocysteine Metabolism and Risk of Myocardial Infarction: Relation with Vitamins B ₆ , B ₁₂ , and Folate", <i>Am. J. Epidemiol.</i> , Vol. 143, No. 9, pp. 845-859 (May 1, 1996)
	Vermaak, W.J.H. et al., "Vitamin B ₆ and coronary artery disease. Epidemiological observations and case studies", <i>Atherosclerosis</i> , Vol. 63, pp. 235-238 (February 1987)
	Vidrio, H., "Interaction with Pyridoxal as a Possible Mechanism of Hydralazine Hypotension", <i>Journal of Cardiovascular Pharmacology</i> , Vol. 15, pp. 150-156 (1990).
	Viscontini, V. et al., "Über einige Derivate des Pyridoxals", <i>Helvetica Chimica Acta</i> , Vol. 34, No. 296, pp. 2438-2439 (1951)
	Volpe, J.J., "Management of Neonatal Seizures", <i>Critical Care Medicine</i> , Vol. 5, No. 1, pp. 43-49 (Jan-Feb 1977)
	Windebank, A., "Neurotoxicity of Pyridoxine Analogs Is Related to Coenzyme Structure", <i>Neurochemical Pathology</i> , Vol. 3, pp. 159-167 (1985)
	Yarat, A. et al., "Effect of vitamin B ₆ on lenses of diabetic rats", <i>Indian Journal of Experimental Biology</i> , Vol. 36, pp. 1269-1272 (December 1998)
	Zempleni, J. et al., "The utilization of intravenously infused pyridoxine in humans", <i>Clinica Chimica Acta</i> , Vol. 229, Nos. 1, 2, pp. 27-36 (September 1994)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	